Text Mining and Drug Discovery Analysis: A Comprehensive Approach to Investigate Diabetes-Induced Osteoporosis

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2024 Jan 22

PMID 38250601

Authors

Chenfeng Wang

Yihe Hu

Feng Liang

Affiliations

Soon will be listed here.

Abstract

Osteoporosis (OP) and diabetes are prevalent diseases in orthopedic and endocrinology departments, with OP potentially arising as a complication of diabetes. However, the mechanism underlying diabetes-induced osteoporosis (DOP) remains enigmatic, and drug discovery in this domain is restricted, hindering research into the DOP's etiology and treatment. With the ultimate goal of preventing OP in diabetic patients, the objective of this study is to mine the genes and pathways linked to DOP using bioinformatics and databases. The present study employed text mining as the initial approach to retrieve genes commonly associated with diabetes and OP. Subsequently, functional annotation was conducted to investigate the roles and functionalities. In order to explore the interactions between proteins relevant to DOP, we constructed protein-protein interaction (PPI) networks. Furthermore, to obtain key genes and candidate drugs for DOP treatment, we conducted drug-gene interaction (DGI) analysis, complemented by a thorough examination of transcriptional factors (TFs)-miRNA co-regulation. The results through text mining revealed 110 genes that are commonly associated with both diabetes and OP. Subsequent enrichment analysis narrowed down the list to 95 symbols that were involved in PPI analysis. After DGI analysis, we identified 7 genes targeted by 11 drugs, which represent candidates for treating DOP. This study unveils ANDECALIXIMAB, SILTUXIMAB, OLOKIZUMAB, SECUKINUMAB, and IXEKIZUMAB as promising potential drugs for DOP treatment, demonstrating the significance of utilizing text mining and pathway analysis to investigate disease mechanisms and explore existing therapeutic options.

References

Zawada A, Ratajczak A, Rychter A, Szymczak-Tomczak A, Dobrowolska A, Krela-Kazmierczak I . Treatment of Diabetes and Osteoporosis-A Reciprocal Risk?. Biomedicines. 2022; 10(9). PMC: 9495959. DOI: 10.3390/biomedicines10092191. View

Huang H, Luo L, Liu Z, Li Y, Tong Z, Liu Z . Role of TNF-α and FGF-2 in the Fracture Healing Disorder of Type 2 Diabetes Model Induced by High Fat Diet Followed by Streptozotocin. Diabetes Metab Syndr Obes. 2020; 13:2279-2288. PMC: 7335275. DOI: 10.2147/DMSO.S231735. View

Rong K, Lang Y, Zhou Y, Ni L, Wang L, Wang L . Risk Genetic Variants () for Osteoporosis in Han Population from Northwest China. J Inflamm Res. 2023; 16:1091-1102. PMC: 10024466. DOI: 10.2147/JIR.S396914. View

Sheu A, Greenfield J, White C, Center J . Assessment and treatment of osteoporosis and fractures in type 2 diabetes. Trends Endocrinol Metab. 2022; 33(5):333-344. DOI: 10.1016/j.tem.2022.02.006. View

Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S . IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999; 103(9):1345-52. PMC: 408356. DOI: 10.1172/JCI5703. View

Dos Santos Haber J, Barbalho S, Sgarbi J, de Argollo Haber R, de Labio R, Fornari Laurindo L . The Relationship between Type 1 Diabetes Mellitus, TNF-α, and IL-10 Gene Expression. Biomedicines. 2023; 11(4). PMC: 10135733. DOI: 10.3390/biomedicines11041120. View

Horiuchi K, Kimura T, Miyamoto T, Miyamoto K, Akiyama H, Takaishi H . Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF. J Immunol. 2009; 182(4):2093-101. PMC: 2924677. DOI: 10.4049/jimmunol.0802491. View

Foley N, ONeill L . miR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. J Leukoc Biol. 2012; 92(3):521-7. DOI: 10.1189/jlb.0312160. View

Sandborn W, Bhandari B, Randall C, Younes Z, Romanczyk T, Xin Y . Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018; 12(9):1021-1029. PMC: 6113706. DOI: 10.1093/ecco-jcc/jjy049. View

10.

Paller A, Seyger M, Magarinos G, Pinter A, Cather J, Rodriguez-Capriles C . Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial. JAMA Dermatol. 2022; 158(5):533-541. PMC: 9008559. DOI: 10.1001/jamadermatol.2022.0655. View

11.

Salari-Moghaddam A, Sadeghi O, Keshteli A, Larijani B, Esmaillzadeh A . Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies. Osteoporos Int. 2019; 30(6):1167-1173. DOI: 10.1007/s00198-019-04948-1. View

12.

Saxena M, Srivastava N, Banerjee M . Association of IL-6, TNF-α and IL-10 gene polymorphisms with type 2 diabetes mellitus. Mol Biol Rep. 2013; 40(11):6271-9. DOI: 10.1007/s11033-013-2739-4. View

13.

Wang F, Rong P, Wang J, Yu X, Wang N, Wang S . Anti-osteoporosis effects and regulatory mechanism of based on network pharmacology and experimental validation. Food Funct. 2022; 13(11):6419-6432. DOI: 10.1039/d2fo00952h. View

14.

Bhadricha H, Patel V, Singh A, Savardekar L, Patil A, Surve S . Increased frequency of Th17 cells and IL-17 levels are associated with low bone mineral density in postmenopausal women. Sci Rep. 2021; 11(1):16155. PMC: 8352954. DOI: 10.1038/s41598-021-95640-0. View

15.

Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova D . Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2021; 81(4):469-479. PMC: 8921576. DOI: 10.1136/annrheumdis-2021-219876. View

16.

Asadipooya K, Uy E . Advanced Glycation End Products (AGEs), Receptor for AGEs, Diabetes, and Bone: Review of the Literature. J Endocr Soc. 2019; 3(10):1799-1818. PMC: 6734192. DOI: 10.1210/js.2019-00160. View

17.

van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A . Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022; 6(16):4773-4781. PMC: 9631655. DOI: 10.1182/bloodadvances.2022007112. View

18.

Naganawa T, Xiao L, Abogunde E, Sobue T, Kalajzic I, Sabbieti M . In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. Biochem Biophys Res Commun. 2005; 339(2):490-8. DOI: 10.1016/j.bbrc.2005.10.215. View

19.

Hidayat K, Du X, Wu M, Shi B . The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies. Obes Rev. 2019; 20(10):1494-1503. DOI: 10.1111/obr.12885. View

20.

Ma Y, Ran D, Zhao H, Song R, Zou H, Gu J . Cadmium exposure triggers osteoporosis in duck via P2X7/PI3K/AKT-mediated osteoblast and osteoclast differentiation. Sci Total Environ. 2020; 750:141638. DOI: 10.1016/j.scitotenv.2020.141638. View